Best Life Sciences Platforms and Tools Companies in Wisconsin, United States
The 57 best Life Sciences Platforms and Tools companies in Wisconsin, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellular Dynamics.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Wisconsin
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellular Dynamics Human iPSC-derived cells and services for research, drug discovery, and therapy | $130M | 152 mo ago | — | James Thomson Founder | — | — | 520 patents Manufacturing and analytical technologies for advanced cell therapies and engineered immune cells | — |
| 2 | Farcast Biosciences Developer of a system for preserving the tumor microenvironment | $85M | 96 mo ago | 24 24 → 48 (+100%) | Pradip Majumder Co-Founder | Wix eCommerceWixSentry+16 | Top 50M | — | — |
| 3 | FUJIFILM Cellular Dynamics Provider of induced pluripotent stem cells for cell therapy | $62M | 164 mo ago | 150 | Takeshi Yamamoto Chairman & CEO | Cart FunctionalityMagentoWordPress+32 | Top 5M | 277 patents Manufacturing, purification, and dosing analytics for therapeutic cell and tissue products | — |
| 4 | Scarab Genomics Developer of bioengineered E.coli strains for a range of applications | $26M | 22 mo ago | 16 | — | — | — | 148 patents Engineering reduced-genome microbes for high-yield recombinant protein production | — |
| 5 | Invenra Pioneering bispecific and trispecific antibody discovery and development for novel therapies | $21M | 93 mo ago | 97 97 → 57 (-41%) | — | — | — | 79 patents Engineering multispecific antibody constructs and heterodimerization platforms for therapeutic proteins. | — |
| 6 | EraGen Biosciences Molecular Reagent Products and molecular diagnostic products for early detection and monitoring of cancer… | $21M | 214 mo ago | 50 | — | — | — | 49 patents Patents concentrated in chemistry & materials | — |
| 7 | BioSentinel Innovative BoNT detection and potency testing solutions for biodefense and pharmaceutical applications | $21M | 176 mo ago | 16 | — | — | — | 14 patents FRET-based protease assays for botulinum toxin detection and related enzymatic screening | — |
| 8 | Brainxell Neural stem cells and progenitor cells for life science research | $16M | 34 mo ago | 37 | Su Chun Zhang Founder | — | — | 8 patents Manufacturing stem‑cell derived dopaminergic and spinal GABAergic neuronal progenitors | 1 launch |
| 9 | NorthStar Medical Radioisotopes Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market | $15M | 14 mo ago | 305 | — | WordPressMySQLPHP+18 | Top 10M | — | 2 job openings · 1 partnership |
| 10 | InvivoSciences Precision medicine company personalizing drug development with 3D micro-tissue technology | $15M | 45 mo ago | 6 | — | — | — | 20 patents Automated 3D cardiac tissue and stem‑cell culture platforms for drug screening and therapy | — |
| 11 | Stemina Biomarker Discovery Human in vitro toxicity testing for drug, food, and product safety | $11M | 121 mo ago | 14 | — | — | — | 78 patents Metabolomic biomarker assays for cardiotoxicity, developmental toxicity, and autism diagnostics | — |
| 12 | Platypus Technologies Provider of custom metal, optical, and patterned thin film coatings | $7M | 53 mo ago | 10 | — | WordPressMySQLPHP+22 | Top 5M | 88 patents UAV aerial imaging, surveillance, and data indexing; rock-climbing safety hardware solutions. | — |
| 13 | Mirus Bio Developer of transfection reagents and electroporation products | $7M | 214 mo ago | 33 33 → 63 (+91%) | — | WordPressSalesforceSalesforce Service Cloud+30 | Top 5M | — | — |
| 14 | Stem Pharm Engineering human biology for neurologic drug discovery with advanced in vitro models | $6M | 7 mo ago | 10 | — | Cart FunctionalitySquarespace CommerceSquarespace+9 | Top 50M | — | — |
| 15 | Semba Biosciences Provider of systems for molecular separation based on simulated moving bed chromatography (SMBC) | $6M | 91 mo ago | 13 | — | — | — | 38 patents High‑flow industrial fluid control valve blocks for enhanced fluid handling systems | — |
| 16 | Lucigen Genomics solutions provider: reagents, instruments, and services for life science research | $5M | 136 mo ago | 65 | — | — | — | 45 patents Engineered DNA polymerases and nucleic‑acid diagnostic kits for molecular detection and sample analysis | 2 launchs · 1 partnership |
| 17 | Biosystem Development Develops and manufactures the AssayMAP for automating sample preparation and analysis | $4M | 179 mo ago | 5 | Scott Fulton Ex-CEO and Founder | — | — | — | — |
| 18 | Intuitive Bio Immunoassay products and services for biomedical research, enhancing lab effectiveness | $4M | 81 mo ago | 9 | — | — | — | — | — |
| 19 | Prodesse Prodesse develops molecular diagnostic reagents for infectious disease applications. | $4M | 251 mo ago | — | Stephen MacMillan CEO & Chairman | — | — | — | — |
| 20 | Neurosetta Provider of human stem cell-derived platform for high-throughput modeling of human brain and spinal cord… | $3M | 14 mo ago | — | Randolph Ashton Co-Founder & CEO | — | — | — | — |
| 21 | Flex Biomedical Developing novel orthopedic treatments and diagnostics for injuries and diseases | $3M | 169 mo ago | 2 | Sal Braico Ex-CEO | — | — | — | — |
| 22 | Proteovista Provider of bioinformatics services and DNA-binding assay development | $3M | 40 mo ago | 5 | Mary Ozers Co-Founder | — | — | 4 patents High-throughput SNP genotyping microarray technology for genetic analysis | — |
| 23 | Dianomi Therapeutics Developer of therapies for treating inflammatory diseases | $3M | 70 mo ago | 7 | — | — | — | — | — |
| 24 | Primorigen A stem cell assay, tool & reagent company | $2M | 135 mo ago | — | Thomas Burke CEO | — | — | — | — |
| 25 | Salus Discovery Molecular diagnostics innovator creating impactful solutions for real-world problems | $2M | 14 mo ago | 16 | Dave Beebe CEO & President | — | — | 56 patents Microfluidic bioseparation platforms for target isolation and stable interface chemistries. | — |
| 26 | Thermagenix PCR additives enhancing polymerase specificity and fidelity for superior amplicons | $2M | 83 mo ago | 6 | — | — | — | — | — |
| 27 | BellBrook Labs Specialty company engaged in drug discovery and biological research by providing screening solutions for… | $2M | 21 mo ago | 18 | Robert Lowery President & CEO | Cart FunctionalityWooCommerceWordPress+14 | Top 10M | 56 patents Small-molecule cGAS inhibitors for immunotherapy and inflammatory disease treatment | 1 launch |
| 28 | Microscopy Innovations Developer of sample preparation system for the electron microscope | $1M | 123 mo ago | 6 | Steven Goodman Founder | — | — | — | 1 launch |
| 29 | Aurora Spectral Technologies Develops micro-spectroscopy imaging systems | $1M | 156 mo ago | 3 | Valerica Raicu Founder | — | — | — | — |
| 30 | SonoPlot Microplotter systems for printed electronics and life science applications | $424K | 202 mo ago | 4 | Kirk Hogan Co-Founder | Cart FunctionalitySquarespace CommerceSquarespace+20 | Top 10M | 2 patents Sensors for detecting user interaction with physical objects | — |
| 31 | Nano Red Biotech Developer of IR-activated, liposome-based drug delivery technologies | $247K | 64 mo ago | 3 | Johnathan Ebben Founder | — | — | — | — |
| 32 | Pan Genome Systems Vaccines and diagnostics for animal health | $200K | 60 mo ago | 3 | — | — | — | — | — |
| 33 | Promega Provider of genomics, protein analysis and expression, drug discovery, and genetic identification products | — | 138 mo ago | 659 | — | — | — | 1,703 patents Bioluminescent reporter enzymes and assay reagents for molecular and cellular diagnostics | — |
Top 12 Life Sciences Platforms and Tools companies in Wisconsin
#1
Funding Raised · Madison, Wisconsin · founded 2015 · 10 employees$5.9Mraised▾
Engineering human biology for neurologic drug discovery with advanced in vitro models. This company specializes in physiologically relevant human neural organoids featuring microglia for neuroimmune drug discovery. They offer comprehensive drug discovery services and partnerships, including neurologic disease modeling, target discovery, phenotypic drug screening, and neurotoxicity assessments. They also provide synthetic substrates, such as chemically-defined hydrogels and pre-coated cell culture plates, to improve outcomes for cell-based applications. Their team of experienced scientists designs and executes studies to generate new insights, supporting the movement to reduce animal testing in drug development. They focus on advancing research in areas like Alzheimer’s disease and neuroinflammatory diseases through innovative in vitro models.
- Dec 2025Grant (prize money)$406.5K
- Sep 2024Grant (prize money)$500K
- Sep 2023Grant (prize money)$554.9K
- Jul 2023Grant (prize money)$406.5K
#2
Series B · Madison, Wisconsin · founded 2006 · 305 employees$15.1Mraised▾
Provider of sourcing, purification, and separation technologies for the Nuclear Medicine market. Its patented technologies include innovative non-uranium-based molybdenum-99 production methods, a novel separation chemistry system, and tools for the nuclear medicine market. Products include Non-HEU 99-Molybdenum and RadioGenix intelligent isotope separation system. Claims to be the first domestic producer of 99-Molybdenum and the only supplier of Non-HEU material.
- May 2025Grant (prize money)$10.7M
- Jul 2019Grant (prize money)$15M
- Apr 2019Conventional Debt$75M
- Oct 2015Grant (prize money)$11.8M
#3
Funding Raised · Madison, Wisconsin · founded 2002 · 16 employees$25.9Mraised▾
Developer of bioengineered E.coli strains for a range of applications. The company has developed clean genome E. coli, a unique, patented set of bacterial hosts for reliable, high-efficiency production of protein and nucleic acid biopharmaceuticals. The product line includes vaccine carrier proteins, vectors, and diagnosis kits.
- Sep 2024Grant (prize money)$842.2K
- Jul 2020Grant (prize money)$2.9M
- Jan 2019Grant (prize money)$1.8M
- Dec 2016Grant (prize money)$1.7M
#4
Funding Raised · Madison, Wisconsin · founded 2018$3.4Mraised▾
Provider of human stem cell-derived platform for high-throughput modeling of human brain and spinal cord development. The platform utilizes human stem cell-derived arrays, known as RosetteArrays, to model early human brain and spinal cord development, enabling the discovery of potential toxic compounds.
- May 2025Grant (prize money)$1.7M
- Jan 2022Grant (prize money)$1.7M
#5
Funding Raised · Madison, Wisconsin · founded 2013 · 16 employees$2.5Mraised▾
Molecular diagnostics innovator creating impactful solutions for real-world problems. The company pioneers new approaches to molecular diagnostics, focusing on simple yet impactful solutions. Their technology portfolio continuously evolves to address long-standing problems in the health sciences. Expertise spans physics, biochemistry, engineering, microfluidics, informatics, cancer, and infectious disease biology. Technologies include analyte pre-concentration and ultra-fast analyte extraction, concentration, and purification. These technologies cater to diverse sample types, offering streamlined solutions for diagnostics and research. The company fosters collaboration between academic research and industry, integrating novel technology development with emerging applications. Their innovations aim to improve testing sensitivity, reduce plastic usage, save time, and simplify processes.
- Apr 2025Grant (prize money)$275.5K
- Feb 2025Grant (prize money)$2.2M
#6
Seed · Madison, Wisconsin · founded 2002 · 18 employees$1.9Mraised▾
BellBrook Labs specializes in drug discovery and biological research by providing screening solutions for enzymes and phenotypic assays. Its product portfolio includes Transcreener to screen different enzymes including validated targets such as kinases, ATPases, GTPases etc, Iuvo to enable highly miniaturized tissue-like cell models and quantitative cell motility assays and other Assay development & Molecule screening technologies. The company received Wisconsin Development Fund awards in 2014
- Sep 2024Grant (prize money)$270.9K
- Aug 2021Grant (prize money)$390.5K
- Sep 2020Grant (prize money)$300K
- Jun 2019Grant (prize money)$1.8M
#7
Series B · Madison, Wisconsin · founded 2015 · 37 employees$16.4Mraised▾
BrainXell develops neural stem cells and progenitor stem cells for life science research. Its platform technology has been developed by researchers at University of Wisconsin-Madison and enables the large scale production of neural progenitor and stem cells from induced pluripotent stem cells (iPSCs) or embryonic stem cells. The company claims that its process can produce up to two billion neurons. BrainXell's product line includes spinal cord motor neurons, midbrain dopaminergic neurons, glutamatergic neurons, GABAergic neurons and mixed cortical neurons, while striatal GABAergic neurons, serotonergic neurons, basal forebrain cholinergic neurons, and astrocytes are under development. The company licenses its iPSCs from iPS Japan.
- Aug 2023Grant (prize money)$275.6K
- Aug 2021Series B$13.2M
- May 2021Grant (prize money)$255.2K
- Sep 2019Grant (prize money)$224.8K
#8
Acquired · Madison, Wisconsin · founded 2004$129.7Mraised▾
Human iPSC-derived cells and services for research, drug discovery, and therapy. They offer a comprehensive portfolio of human induced pluripotent stem cell (iPSC) products and custom services. These include cardiac cells, neural cells, hematopoietic and other cells, along with specialized media and supplements. Their offerings support applications in disease modeling, drug discovery, toxicology/safety pharmacology, and stem cell banking. They provide both research-grade and GMP iPSC lines, alongside contract development and manufacturing (CDMO) services for clinical-grade human cells. The company leverages human iPSC technology to revolutionize scientific research and cell therapy. They provide resources like knowledge base, videos, product literature, COA lookup, peer-reviewed publications, poster presentations, news, events, conferences, and webinars. They offer custom services and support various applications in life sciences and therapeutics.
- Nov 2013Grant (prize money)—
- Jun 2013Convertible Debt$20M
- Nov 2012Series B$21M
- Apr 2011Series B$30M
#9
Funding Raised · Madison, Wisconsin · founded 2001 · 6 employees$14.9Mraised▾
Precision medicine company personalizing drug development with 3D micro-tissue technology. They accelerate personalized drug discovery and development using patient-derived and gene-edited human samples. Their automated, scalable, functional 3D engineered micro-human heart tissue platform integrates cell & tissue handling automation, tissue phenotyping assays, computational biology (AI), and human organ/tissue data. This enables rapid identification of safety and efficacy profiles for specific patient groups, cost-effectively prior to clinical trials. They focus on matchmaking treatments for patients, expediting discovery and clinical trials, and supporting post-product launch monitoring. Their technology mitigates clinical trial failure risks and develops patient-specific treatments, particularly for heart failure. They identify repurposing drug pipelines for cardiac fibrosis and expand disease models to validate new targets. They offer high-throughput phenotyping, rare disease modeling using stem cell and gene-editing technologies, and system biology with AI for predicting physiological responses.
- Sep 2022Grant (prize money)$493.7K
- Jun 2019Grant (prize money)$2.1M
- Sep 2018Grant (prize money)$288.5K
- Aug 2016Grant (prize money)$493.9K
#10
Series C · Madison, Wisconsin · founded 2009 · 24 employees$84.5Mraised▾
Developer of a system for preserving the tumor microenvironment. It offers anthropic biological systems, data, and Artificial Intelligence platform to capture the complexity of human tumors and autologous blood samples which are cultured to preservice the microenvironment, tumor architecture and immune cell compartment to conduct ex vivo evaluation of tumor response to drug treatment.
- Jul 2018Series C$43.8M
- Aug 2016Series B$27.4M
- Apr 2015Series B$3.6M
- Oct 2013Series B$6.5M
#11
Series C · Madison, Wisconsin · founded 2004 · 150 employees$61.7Mraised▾
Fujifilm Cellular Dynamics is a provider of induced pluripotent cells for cell therapy. The company has developed techniques for developing and manufacturing induced pluripotent stem (iPS) cells and differentiating them into functional human cells. The company provides induced pluripotent cardiac cells, neural cells, hematopoietic cells and reagents.
- Nov 2012Series C$21M
- Feb 2010Series C$40.6M
- Oct 2008Grant (prize money)$616K
- Jul 2008Grant (prize money)$616K
#12
Funding Raised · Madison, Wisconsin · founded 2011 · 5 employees$3.1Mraised▾
Provider of bioinformatics services and DNA-binding assay development. The company's SNAP technology allows the determination of any DNA-binding molecule by utilizing the massively-multiplexed nature of DNA microarrays. Also, it offers bioinformatics consulting across various applications such as arrays, NGS, and ChIP-seq.
- Mar 2023Grant (prize money)$376.8K
- Sep 2019Grant (prize money)$224.5K
- May 2019Grant (prize money)$569.6K
- Aug 2018Grant (prize money)$222.7K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Wisconsin is moving
A read on the academic research around Bioinformatics in Wisconsin — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 182 papers.
University of Wisconsin–Madison leads Wisconsin's optimistically-toned bioinformatics research, focusing predominantly on genomics, single-cell transcriptomics, and microbial ecology, with breakthroughs dominating recent post-2020 output.
- University of Wisconsin–Madison128
- Medical College of Wisconsin33
- University of Wisconsin System9
- University of Wisconsin–River Falls7
- University of Wisconsin Carbone Cancer Center7
- Gene1→9
- Genome2→10
- Proteomics1→5
- Disease9
- Gene6
- Arabidopsis thaliana6
- Arabidopsis6
- Metabolomics5
- DNA methylation3
- Disease3
- Prostate cancer2
- Clinical trial2
- Personalized medicine2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.